Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10189518 | 0.99 | PTGS1 (0.53) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL410896 | 0.92 | PTGS1 (0.59) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10189515 | 0.90 | ALDH1A1 (0.63) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10189512 | 0.89 | ALDH1A1 (0.49) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10189600 | 0.89 | ALDH1A1 (0.49) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10189548 | 0.88 | ALDH1A1 (0.48) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10189522 | 0.88 | FLT3 (0.54) | PTGS1PTGS2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL10189526 | 0.87 | FLT3 (0.57) | PTGS1PTGS2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL10189596 | 0.86 | ALDH1A1 (0.47) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10189550 | 0.86 | ALDH1A1 (0.47) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS1 2500/4885PTGS2 3488/4885ALDH1A1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.